CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
CG Oncology (NASDAQ: CGON) has announced a conference call and webcast scheduled for April 28, 2025, at 8:00 am ET to discuss the results of their Phase 3 BOND-003 trial. The trial focuses on cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The results will be initially presented at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada on April 26, 2025. Interested parties can access the webcast through the company's Investor Relations website at https://ir.cgoncology.com, with an archive available after the call.
CG Oncology (NASDAQ: CGON) ha annunciato una conference call e una webcast programmate per il 28 aprile 2025 alle 8:00 ET per discutere i risultati del loro trial di Fase 3 BOND-003. Lo studio si concentra sulla monoterapia con cretostimogene per il carcinoma della vescica non muscolo-invasivo (NMIBC) ad alto rischio resistente al BCG.
I risultati saranno presentati inizialmente durante una Sessione Plenaria all'American Urological Association (AUA) Annual Meeting a Las Vegas, Nevada, il 26 aprile 2025. Gli interessati potranno seguire la webcast tramite il sito web delle Relazioni con gli Investitori della società all'indirizzo https://ir.cgoncology.com, con un archivio disponibile dopo la chiamata.
CG Oncology (NASDAQ: CGON) ha anunciado una conferencia telefónica y una transmisión en línea programadas para el 28 de abril de 2025 a las 8:00 am ET para discutir los resultados de su ensayo de Fase 3 BOND-003. El estudio se centra en la monoterapia con cretostimogene para el cáncer de vejiga no músculo invasivo (NMIBC) de alto riesgo que no responde al BCG.
Los resultados se presentarán inicialmente en una Sesión Plenaria en la Reunión Anual de la American Urological Association (AUA) en Las Vegas, Nevada, el 26 de abril de 2025. Las partes interesadas podrán acceder a la transmisión a través del sitio web de Relaciones con Inversionistas de la empresa en https://ir.cgoncology.com, con un archivo disponible después de la llamada.
CG Oncology (NASDAQ: CGON)는 2025년 4월 28일 오전 8시 ET에 3상 BOND-003 임상시험 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 발표했습니다. 이 임상시험은 BCG에 반응하지 않는 고위험 비근육침윤성 방광암(NMIBC)에 대한 크레토스티모진 단독 요법에 중점을 두고 있습니다.
결과는 2025년 4월 26일 네바다주 라스베이거스에서 열리는 미국 비뇨기과학회(AUA) 연례회의 본회의에서 처음 발표될 예정입니다. 관심 있는 분들은 회사 투자자 관계 웹사이트 https://ir.cgoncology.com를 통해 웹캐스트에 접속할 수 있으며, 콜 종료 후 아카이브도 제공됩니다.
CG Oncology (NASDAQ : CGON) a annoncé une conférence téléphonique et une webdiffusion prévues pour le 28 avril 2025 à 8h00 ET afin de discuter des résultats de leur essai de phase 3 BOND-003. Cet essai porte sur la monothérapie au crétostimogène pour le cancer de la vessie non invasif de haut risque, réfractaire au BCG (NMIBC).
Les résultats seront présentés en premier lors d'une session plénière à la réunion annuelle de l'American Urological Association (AUA) à Las Vegas, Nevada, le 26 avril 2025. Les personnes intéressées pourront accéder à la webdiffusion via le site des relations investisseurs de la société à l'adresse https://ir.cgoncology.com, avec un archivage disponible après l'appel.
CG Oncology (NASDAQ: CGON) hat eine Telefonkonferenz und Webcast für den 28. April 2025 um 8:00 Uhr ET angekündigt, um die Ergebnisse ihrer Phase-3-Studie BOND-003 zu besprechen. Die Studie konzentriert sich auf die Cretostimogen-Monotherapie bei hochriskantem BCG-unansprechendem nicht-muskelinvasivem Blasenkarzinom (NMIBC).
Die Ergebnisse werden zunächst in einer Plenarsitzung auf der Jahrestagung der American Urological Association (AUA) in Las Vegas, Nevada, am 26. April 2025 vorgestellt. Interessierte können den Webcast über die Investor-Relations-Website des Unternehmens unter https://ir.cgoncology.com verfolgen; ein Archiv wird nach dem Anruf verfügbar sein.
- None.
- None.
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada.
Individuals can access the webcast via the link on the company's Investor Relations website, https://ir.cgoncology.com. An archive will be available following the completion of the call.
About Bladder Cancer
More than 85,000 people are estimated to be diagnosed with bladder cancer in 2025. NMIBC is the most common form of bladder cancer, representing approximately
About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. Cretostimogene is also being evaluated in a Phase 3 monotherapy clinical trial (PIVOT-006) in patients with intermediate-risk NMIBC. In addition, cretostimogene is being evaluated in an investigator-sponsored clinical trial in combination with nivolumab for the treatment of muscle invasive bladder cancer.
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Chau Cheng
Vice President, Investor Relations, CG Oncology
(949) 342-8939
chau.cheng@cgoncology.com
FAQ
When will CG Oncology (CGON) present the BOND-003 Phase 3 trial results?
What is the BOND-003 trial investigating for CGON stock?
How can investors access CGON's BOND-003 trial results webcast?
What type of cancer treatment is CG Oncology (CGON) developing?
